

Chongrui Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4059048/publications.pdf>

Version: 2024-02-01

64
papers

3,964
citations

361296

20
h-index

161767

54
g-index

71
all docs

71
docs citations

71
times ranked

4940
citing authors

#	ARTICLE	IF	CITATIONS
1	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	5.1	1,740
2	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. <i>Oncolimmunology</i> , 2017, 6, e1356145.	2.1	305
3	Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3316-3321.	0.8	233
4	Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. <i>Annals of Oncology</i> , 2018, 29, 945-952.	0.6	197
5	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 33-39.	0.9	156
6	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. <i>British Journal of Cancer</i> , 2017, 116, 568-574.	2.9	155
7	HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	7.7	149
8	A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 96-102.	0.9	146
9	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1368-1375.	0.5	79
10	Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 5480-5488.	3.2	78
11	Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4929-4937.	3.2	67
12	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. <i>Annals of Oncology</i> , 2014, 25, 2385-2391.	0.6	64
13	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 883-889.	0.5	55
14	EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. <i>Thoracic Cancer</i> , 2018, 9, 814-819.	0.8	42
15	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. <i>Journal of Hematology and Oncology</i> , 2016, 9, 86.	6.9	41
16	Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 441-447.	1.1	35
17	The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 51311-51319.	0.8	35
18	Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. <i>Oncotarget</i> , 2016, 7, 65185-65195.	0.8	31

#	ARTICLE	IF	CITATIONS
19	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. <i>EBioMedicine</i> , 2019, 43, 180-187.	2.7	30
20	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? – A literature-based meta-analysis. <i>Journal of Hematology and Oncology</i> , 2012, 5, 62.	6.9	25
21	Effects of epidermal growth factor receptor tyrosine kinase inhibitors alone on EGFR mutant non-small cell lung cancer with brain metastasis. <i>Thoracic Cancer</i> , 2016, 7, 648-654.	0.8	23
22	Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	23
23	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8575-8587.	1.0	21
24	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 596937.	1.3	21
25	Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 635-641.	1.0	19
26	Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. <i>Oncologist</i> , 2014, 19, 1084-1090.	1.9	18
27	Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2014, 86, 219-224.	0.9	17
28	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17
29	A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG) Tj ETQq1 1 0.7843 14 rgBtd/Overl	1.0	14
30	Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1089-1096.	1.5	16
31	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. <i>BMC Cancer</i> , 2019, 19, 369.	1.1	13
32	A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). <i>European Journal of Cancer</i> , 2019, 109, 183-191.	1.3	13
33	An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer. <i>Immunological Investigations</i> , 2009, 38, 665-680.	1.0	12
34	Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 97-102.	0.7	8
35	Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation. <i>Thoracic Cancer</i> , 2017, 8, 51-53.	0.8	8
36	The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 4994-5002.	0.8	8

#	ARTICLE	IF	CITATIONS
37	The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge. <i>Science Bulletin</i> , 2019, 64, 499-503.	4.3	6
38	Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 155-161.	0.8	4
39	P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China. <i>Journal of Thoracic Oncology</i> , 2018, 13, S502.	0.5	4
40	Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9078-9078.	0.8	4
41	P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1899.	0.5	3
42	Liquid biopsy guided precision therapy for lung cancers. <i>Journal of Thoracic Disease</i> , 2018, 10, S4173-S4175.	0.6	3
43	Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. <i>World Journal of Surgical Oncology</i> , 2017, 15, 12.	0.8	2
44	JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S311-S312.	0.5	2
45	Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 495-499.	0.1	1
46	Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?. <i>Nuclear Medicine Communications</i> , 2011, 32, 1113-1120.	0.5	1
47	MA15.06 Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, ACO010. <i>Journal of Thoracic Oncology</i> , 2018, 13, S408-S409.	0.5	1
48	<p>Familial association of lung cancer with liver cancer in first-degree relatives</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5813-5819.	0.9	1
49	Overall survival in patients with advanced non-small cell lung cancer harboring concomitant <i>EGFR</i> mutations and <i>ALK</i> rearrangements: A cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19010-e19010.	0.8	1
50	MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19047-e19047.	0.8	1
51	First-line versus second or further-line crizotinib for trial patients with advanced non-small-cell lung cancer harboring <i>ALK</i> rearrangements.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19139-e19139.	0.8	1
52	D3-05: Prediction of best objective response and survival to the first-line chemotherapy in advanced non-small cell lung cancer by 18FDG-PET. <i>Journal of Thoracic Oncology</i> , 2007, 2, S398.	0.5	0
53	P2-151: Change of the EGFR expression and downstream signal pathway in A549 cell Treated with ZD1839. <i>Journal of Thoracic Oncology</i> , 2007, 2, S551.	0.5	0
54	P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1195-S1196.	0.5	0

#	ARTICLE	IF	CITATIONS
55	JCES 01.26 Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC. Journal of Thoracic Oncology, 2017, 12, S1739.	0.5	0
56	EGFR mutation in early-stage and advanced-stage lung adenocarcinoma: Based on large date in China. Annals of Oncology, 2017, 28, x120.	0.6	0
57	P1.03-34 Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI. Journal of Thoracic Oncology, 2018, 13, S524-S525.	0.5	0
58	P1.01-85 Treatment for Advanced NSCLC with EGFR Mutations and De Novo MET Amplification/Overexpression. Journal of Thoracic Oncology, 2019, 14, S393.	0.5	0
59	P3-110: Tumor histology and N-score predict survival with gefitinib in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S726.	0.5	0
60	P2-053: Establishment, identification and examination about the EGFR status of the lung cancer cell line. Journal of Thoracic Oncology, 2007, 2, S511.	0.5	0
61	Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.. Journal of Clinical Oncology, 2010, 28, TPS284-TPS284.	0.8	0
62	Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS).. Journal of Clinical Oncology, 2018, 36, e24181-e24181.	0.8	0
63	Familial association of lung cancer patients with liver cancer in first-degree relatives.. Journal of Clinical Oncology, 2018, 36, e13597-e13597.	0.8	0
64	Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors. Future Oncology, 2022, , .	1.1	0